Assessment of body composition in breast cancer patients: concordance between transverse computed tomography analysis at the fourth thoracic and third lumbar vertebrae.
| Autor: | Daly A; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Newman L; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom., Thomas A; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Munro A; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom., Spence C; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom., Long J; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom., Arnott J; Salisbury District Hospital, Salisbury, United Kingdom., Durkin K; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Layfield D; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Heetun A; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom., Wootton S; Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; NIHR Cancer and Nutrition Collaboration, Southampton, United Kingdom., Copson ER; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom., Cutress RI; Cancer Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in nutrition [Front Nutr] 2024 Apr 23; Vol. 11, pp. 1366768. Date of Electronic Publication: 2024 Apr 23 (Print Publication: 2024). |
| DOI: | 10.3389/fnut.2024.1366768 |
| Abstrakt: | Introduction: Specific body composition markers derived from L3 axial computed tomography (CT) images predict clinical cancer outcomes, including chemotherapy toxicity and survival. However, this method is only applicable to those undergoing lumbar (L3) CT scanning, which is not universally conducted in early breast cancer cases. This study aimed to evaluate CT analysis at T4 as a feasible alternative marker of body composition in breast cancer. Method: All patients participated in the Investigating Outcomes from Breast Cancer: Correlating Genetic, Immunological, and Nutritional (BeGIN) Predictors observational cohort study (REC reference number: 14/EE/1297). Staging chest-abdomen-pelvic CT scan images from 24 women diagnosed with early breast cancer at University Hospital Southampton were analysed. Adipose tissue, skeletal muscle, and muscle attenuation were measured from the transverse CT slices' cross-sectional area (CSA) at T4 and L3. Adipose tissue and skeletal muscle area measurements were adjusted for height. Spearman's rank correlation coefficient analysis was used to determine concordance between body composition measurements using CT analysis at L3 and T4 regions. Results: Derived estimates for total adipose tissue, subcutaneous adipose tissue, and intramuscular adipose tissue mass following adjustment for height were highly concordant when determined from CSAs of CT slices at T4 and L3 (R Discussion: These results suggest that the CT analysis at T4 and L3 provides highly concordant markers for total adipose, subcutaneous adipose, and intramuscular adipose estimation, but not VAT, in this breast cancer population. High concordance between T4 and L3 was also found when assessing skeletal muscle attenuation. Lower concordance was observed for the estimates of skeletal muscle area, potentially explained by differences in the quantity and proportions of axial and appendicular muscle between the thorax and abdomen. Future studies will determine the value of T4 metrics as predictive tools for clinical outcomes in breast cancer. Competing Interests: EC – Personal payments made for participation in advisory panels (Eli-Lilly Nanostring, AstraZeneca). Personal payments for delivery of educational lectures (Roche, Novartis, Pfizer, and AstraZeneca). Travel, accommodation, and registration fee provided for attendance at ESMO 2019 (Roche). Member of Grant Awards Panel Expert Advisory Group (WCRF). SW – Holds an investigator-led Collaborative Research Agreement between Seca Medical Measuring Systems and Scales and the University of Southampton/University Hospital Southampton NHS Foundation Trust. Seca played no part in the design, conduct or interpretation of the work reported in this publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Daly, Newman, Thomas, Munro, Spence, Long, Arnott, Durkin, Layfield, Heetun, Wootton, Copson and Cutress.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|